Shareholders of Dr Reddys Laboratories approved a final dividend of ₹8 per equity share for the financial year ended March 31, 2026, during its 42nd Annual General Meeting held on July 23, 2026. The virtual meeting, conducted via Video Conferencing and Other Audio-Visual Means (OAVM), also witnessed the re-appointment of Chairman K Satish Reddy and the appointment of Deloitte Haskins & Sells LLP as statutory auditors for a five-year term. The approval of these key governance and shareholder return measures underscores continued investor confidence in the company’s leadership and financial stewardship.

The meeting commenced at 11:00 AM IST with 86 members holding 22,25,59,764 shares in attendance, satisfying the quorum requirements under Article 70 of the Articles of Association. Chairman K Satish Reddy presided over the proceedings, which were scrutinized by Atul Mehta of Mehta & Mehta, Company Secretaries. In compliance with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, voting was conducted through remote e-voting from July 19 to July 22, 2026, and via electronic voting during the AGM. All seven resolutions on the agenda were declared passed by the requisite majority.

Key Resolutions Passed

The Board of Directors sought shareholder approval for several ordinary and special resolutions. The dividend declaration received near-unanimous support, with 99.99% of votes cast in favor. Similarly, the adoption of the audited financial statements for FY26 passed with 99.99% approval. The re-appointment of K Satish Reddy, who retires by rotation, secured 99.38% support.

Governance and Auditor Appointments

The company appointed M/s. Deloitte Haskins & Sells LLP as its statutory auditors for a period of five consecutive years, commencing from the conclusion of the 42nd AGM till the conclusion of the 47th AGM. This resolution passed with 99.98% support. Additionally, the remuneration payable to cost auditors M/s. Sagar & Associates for the financial year ending March 31, 2027, was ratified with 99.99% approval.

In terms of board composition, shareholders approved the re-appointment of Dr. K P Krishnan as an Independent Director for a second term of five years, effective from January 7, 2027, to January 6, 2032. The resolution received 97.27% support. The company also appointed Mr. Srikanth Velamakanni as an Independent Director for a five-year term, effective from July 1, 2026, to June 30, 2031. This special resolution passed with 91.35% of votes in favor.

What the Numbers Show

The voting patterns reveal strong institutional alignment with management proposals, particularly on financial and audit matters. The promoter group, holding 22,23,05,640 shares, voted unanimously in favor of all resolutions. Public institutions accounted for approximately 91% of the total votes polled, indicating high engagement from large investors. While the appointment of Srikanth Velamakanni faced notable dissent (8.65% against), it still comfortably met the three-to-one majority requirement for special resolutions, reflecting broad-based acceptance of the board’s governance strategy.

Dr Reddy's Laboratories reported a year-on-year decline in revenue to ₹81B for Q1FY27, falling short of analyst estimates of ₹88.05B and compared to ₹85.72B in the same period last year. The results were primarily impacted by a ₹2.40B charge from semaglutide API provisions and associated costs, alongside lower lenalidomide sales in North America. This miss signals margin pressure despite underlying growth in emerging markets and India, affecting investor sentiment ahead of future earnings reports.

The Board of Directors approved the unaudited standalone and consolidated financial results at their meeting held on July 22, 2026, based on recommendations from the Audit Committee. The results were filed with stock exchanges pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company maintained a net cash surplus of ₹3,058 Cr as of June 30, 2026.

Financial Performance

The company's results missed analyst expectations across all key metrics, with revenue, EBITDA, and net profit all coming in below estimates. The following table summarises the reported performance against prior year figures and analyst estimates:

Excluding the semaglutide API impact, the company's financials showed stronger underlying performance, with an EBITDA margin of 15.4% and a profit before tax margin of 9.8%. The reported Return on Capital Employed (RoCE) stood at 5.3%, which would have been 8% excluding the API-related impact. Dr Reddy's highlighted healthy double-digit growth in its base business, excluding the impact of lenalidomide and specific API-related charges.

Business Highlights

Dr Reddy's achieved several strategic milestones during the quarter, including the first-to-market launch in the US of the anti-cancer drug bosutinib 400mg with 180-day exclusivity. The company became the first to launch a generic semaglutide injection for Type 2 Diabetes in Canada and introduced generic semaglutide tablets in India. Additionally, the nutrition offering Celevida GLP+ was launched through a collaboration with Nestlé.

The company received a Form 483 with seven observations following a Pre-Approval Inspection (PAI) at its biologics facility in Bachupally in June 2026, to which it responded within the stipulated timeline. Certain batches of semaglutide were found to be out of specification due to an issue associated with the API. On the sustainability front, Dr Reddy's celebrated 25 years of listing on the NYSE and was ranked in the top 1% globally by FTSE Russell.

What the Numbers Show

The divergence between reported margins (10.62%) and adjusted margins (15.4%) highlights the significant drag from one-time charges rather than operational inefficiency. While North America revenue decreased 35% year-on-year to ₹2,205 Cr due to lenalidomide, Emerging Markets grew 31% to ₹1,833 Cr, driven by new product launches and favourable foreign exchange rates. India revenue rose 17% to ₹1,718 Cr, supported by new brand launches and volume growth, while Europe increased 13% to ₹1,444 Cr aided by generics launches and forex tailwinds.